Spot­light­ing sub­group analy­sis, Ther­a­vance tries to carve out 'nar­row, but crit­i­cal­ly im­por­tan­t' mar­ket for failed drug

When Ther­a­vance Bio­phar­ma re­vealed last Sep­tem­ber that its first Phase III tri­al for am­prelox­e­tine had end­ed in fail­ure, it de­mot­ed the drug from lead sta­tus and laid off 75% of its work­force to stay afloat. But CEO Rick Win­ning­ham vowed to “con­tin­ue to an­a­lyze the da­ta to bet­ter un­der­stand the find­ings.”

As it re­ports a sec­ond flop for the same can­di­date, it’s stick­ing to the same ap­proach to find a sil­ver lin­ing in the da­ta.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.